A5012570915- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Venous Thromboembolism Diagnosis and Management
- Acute Ischemic Stroke Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Acute Myocardial Infarction Research
- Medication Adherence and Compliance
- Heart Rate Variability and Autonomic Control
- ECG Monitoring and Analysis
- Cerebrovascular and Carotid Artery Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Pregnancy and preeclampsia studies
- Cardiovascular Function and Risk Factors
- Cardiovascular Effects of Exercise
- Birth, Development, and Health
- Pharmaceutical Practices and Patient Outcomes
- Cardiovascular Issues in Pregnancy
- Health disparities and outcomes
Liverpool Heart and Chest Hospital
2019-2025
University of Liverpool
2015-2025
Aalborg University
2016-2025
Liverpool John Moores University
2022-2025
North Denmark Region
2025
Centre for Life
2024
University of Birmingham
2013-2023
University of Aberdeen
2022
Sandwell & West Birmingham Hospitals NHS Trust
2003-2022
Örebro University
2022
Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It also read 60 mginstead mg (use with caution in 'supranormal' renal function).In the above-indicated cell, a footnote has been added to state: Edoxaban used patients high creatinine clearance only after careful evaluation individual thromboembolic and bleeding risk.Supplementary 'Dose reduction selected patients' 16). reduced 30 once daily if any...
The current manuscript is the second update of original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Guide on use new oral anticoagulants patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel Updated non-vitamin K antagonist 2015;17:1467-1507]. Non-vitamin (NOACs) are an alternative for vitamin antagonists (VKAs) to prevent stroke fibrillation (AF) and have emerged as preferred choice, particularly newly started...
Both atrial fibrillation and chronic kidney disease increase the risk of stroke systemic thromboembolism. However, these risks, effects antithrombotic treatment, have not been thoroughly investigated in patients with both conditions.
CV Cardiovascular CYP Cytochrome P (CYP) Unfractionated heparin ULN Upper limit of normal VENTURE-AF Active-controlled multi-center study with blind-adjudication designed to evaluate the safety uninterrupted Rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for non-valvular Atrial Fibrillation VHD Valvular heart disease VKA Vitamin antagonist VTE Venous thromboembolic event WOEST What is Optimal antiplatelet anticoagulant therapy patients oral anticoagulation...
Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke thrombo-embolism, this common cardiac arrhythmia represents major healthcare burden in Europe.1 Stroke prevention is central to the management AF patients, with 2012 focused update European Society Cardiology (ESC) guidelines2 recommending oral anticoagulation (OAC) using well-controlled adjusted dose vitamin K antagonists (VKAs, e.g. warfarin) or non-VKA anticoagulants (NOACs, previously referred as...
Background and Purpose— The risk of stroke in patients with atrial fibrillation (AF) is not homogeneous, various clinical factors have informed the development stratification schemes (RSS). Among anticoagulated cohorts, emphasis should be on identification who remain at high for despite anticoagulation. Methods— We investigated predictors thromboembolism (TE) an AF trial cohort (n=7329 subjects) tested predictive value contemporary RSS this cohort: CHADS 2 , Framingham, NICE 2006, American...
The purpose of this study was to determine the impact symptoms depression and anxiety on mortality quality life in patients hospitalized for acute myocardial infarction (MI).The Beck Depression Inventory State-Trait Anxiety were completed by 288 MI. Twelve-month survival status ascertained, among survivors assessed at 12 months using Dartmouth COOP charts.Thirty-one (10.8%) died, 27 cardiac causes, during 12-month follow-up. Symptoms predicted neither nor all-cause mortality. Severity...
Summary It was the aim of this study to determine efficacy and safety vitamin K antagonists (VKAs) acetylsalicylic acid (ASA) in patients with non-valvular atrial fibrillation (AF), separate analyses according predicted thromboembolic bleeding risk. By individual levellinkage nationwide registries, we identified all discharged AF Denmark (n=132,372). For every patient, risk stroke calculated by CHADS2, CHA2DS2-VASc, HAS-BLED. During follow-up, treatment VKA ASA determined time-dependently....
Background At the beginning of June 2020, there were nearly 7 million reported cases coronavirus disease 2019 (COVID-19) worldwide and over 400,000 deaths in people with COVID-19. The objective this study was to determine associations between comorbidities listed Charlson comorbidity index mortality among patients United States Methods findings A retrospective cohort adults COVID-19 from 24 healthcare organizations US conducted. included aged 18–90 years coded their electronic medical...
The concept of net clinical benefit has been used to quantify the balance between risk ischaemic stroke (IS) and intracranial haemorrhage (ICH) with use oral anticoagulant therapy (OAC) in setting non-valvular atrial fibrillation (AF), shown that patients at highest thromboembolism gain greatest from OAC warfarin. There are no data for new OACs, is, dabigatran, rivaroxaban apixaban, as yet. We calculated balancing IS against ICH using Danish National Patient Registry on AF 1997-2008,...
The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], 65-75 years, sex category [female]) is used clinically for stroke risk stratification in atrial fibrillation (AF). Its usefulness a population of patients with failure (HF) unclear.To investigate whether predicts stroke, thromboembolism, and death cohort...